The Food and Drug Administration on Wednesday approved GSK's vaccine for the respiratory syncytial virus, or R.S.V., for adults who are 60 and older, the company said.The vaccine, to be sold as Arexvy, appears to be the first in the world approved for sale to protect older adults.Image An transmission electron microscopic image of R.S.V.Credit...Centers for Disease Control and Prevention The F.D.A. estimates that R.S.V. is associated with 6,000 to 10,000 deaths each year in adults 65 and older and at least 60,000 hospitalizations in that age group.
#years #recommendation #disease-control #european-union #astrazeneca #pfizer-vaccine #authorization #hospitalizations #immune-system #older-adults
[
add
]
[
|
|
...
]